AEterna Zentaris (AEZS)
(Delayed Data from NSDQ)
$5.35 USD
-0.05 (-0.93%)
Updated Jul 26, 2024 02:51 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
AEterna Zentaris Inc. [AEZS]
Reports for Purchase
Showing records 61 - 80 ( 168 total )
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
2012 Results; Phase III Study of ''108 in EC to Start Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Perifosine MM Discontinued, Still See Upside with ''''108 & Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Randomized Phase II Study of AEZS-108 in TNBC Starts, as Expected
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
SPA in Hand for AEZS-108 Phase III, Expect 1Q13 Start; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
ASH Data and Management Update; Programs on Track; Target to $8
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Timeline for AEZS-130 NDA Submission Unchanged; Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
European Patent Granted for AEZS-130 Use as Diagnostic
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
A Fresh Look at Multiple Opportunities; Initiating Coverage at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
What Was Supposed to Be a Quiet Week Turns Into a Busy Week
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M